Brian Piekos, the Chief Financial Officer of $KALV, sold 4,471 shares of the company on 11-24-2025 for an estimated $60,139. We received data on the trade from a recent SEC filing. This was a sale of approximately 29.8% of their shares of this class of stock. Following this trade, they now own 10,529 shares of this class of $KALV stock.
$KALV Insider Trading Activity
$KALV insiders have traded $KALV stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $KALV stock by insiders over the last 6 months:
- BENJAMIN L PALLEIKO (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 8 sales selling 81,525 shares for an estimated $1,190,066.
- CHRISTOPHER YEA (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 6 sales selling 44,229 shares for an estimated $664,189.
- PAUL K. AUDHYA (CHIEF MEDICAL OFFICER) has made 0 purchases and 5 sales selling 16,588 shares for an estimated $224,768.
- BRIAN PIEKOS (Chief Financial Officer) sold 4,471 shares for an estimated $60,139
- NICOLE SWEENY (Chief Commercial Officer) has made 0 purchases and 2 sales selling 3,344 shares for an estimated $44,508.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KALV Hedge Fund Activity
We have seen 80 institutional investors add shares of $KALV stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 3,925,000 shares (-84.0%) from their portfolio in Q3 2025, for an estimated $47,806,500
- MILLENNIUM MANAGEMENT LLC added 1,755,594 shares (+515.4%) to their portfolio in Q3 2025, for an estimated $21,383,134
- GOLDMAN SACHS GROUP INC added 1,665,783 shares (+1239.4%) to their portfolio in Q3 2025, for an estimated $20,289,236
- PARKMAN HEALTHCARE PARTNERS LLC added 1,055,940 shares (+155.5%) to their portfolio in Q3 2025, for an estimated $12,861,349
- AMERIPRISE FINANCIAL INC removed 909,676 shares (-96.2%) from their portfolio in Q3 2025, for an estimated $11,079,853
- FREESTONE GROVE PARTNERS LP added 704,448 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,580,176
- SIO CAPITAL MANAGEMENT, LLC added 683,819 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,328,915
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KALV Analyst Ratings
Wall Street analysts have issued reports on $KALV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 09/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/11/2025
To track analyst ratings and price targets for $KALV, check out Quiver Quantitative's $KALV forecast page.
$KALV Price Targets
Multiple analysts have issued price targets for $KALV recently. We have seen 5 analysts offer price targets for $KALV in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $28.0 on 11/11/2025
- Jonathan Wolleben from JMP Securities set a target price of $28.0 on 09/12/2025
- Serge Belanger from Needham set a target price of $28.0 on 09/12/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $27.0 on 07/11/2025
- Joseph Schwartz from Leerink Partners set a target price of $20.0 on 07/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
